Provided by Tiger Trade Technology Pte. Ltd.

Sarepta Therapeutics

21.03
+0.17000.81%
Post-market: 20.84-0.1900-0.90%19:49 EDT
Volume:2.66M
Turnover:55.56M
Market Cap:2.22B
PE:-15.98
High:21.16
Open:20.56
Low:20.18
Close:20.86
52wk High:25.32
52wk Low:14.68
Shares:105.57M
Float Shares:99.05M
Volume Ratio:0.78
T/O Rate:2.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3161
EPS(LYR):-7.1300
ROE:-9.48%
ROA:-1.13%
PB:1.45
PE(LYR):-2.95

Loading ...

Sarepta Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 30

FDA Advisers Vote Against Capricor's Duchenne Heart Disease Therapy

Reuters
·
Jul 30

Earning Preview: Sarepta Therapeutics Q2 revenue is expected to decrease by 31.25%, and institutional views are mixed leaning bullish

Earnings Agent
·
Jul 30

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Vericel (VCEL), Sarepta Therapeutics (SRPT) and Neumora Therapeutics, Inc. (NMRA)

TIPRANKS
·
Jul 28

Morgan Stanley says Sarepta’s CEO transition brings clarity ahead of catalysts

TIPRANKS
·
Jul 27

Sarepta Gains After Appointing Former AbbVie Executive Severino as CEO

Reuters
·
Jul 27

Sarepta Names Michael Severino CEO, Succeeding Retiring Doug Ingram

Reuters
·
Jul 27

Sarepta Therapeutics - Doug Ingram to Retire and Serve as Advisor Until End of 2026

THOMSON REUTERS
·
Jul 27

Sarepta Therapeutics Appoints Michael Severino, M.d., Chief Executive Officer

THOMSON REUTERS
·
Jul 27

Press Release: Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results

Dow Jones
·
Jul 22

Analysts Offer Insights on Healthcare Companies: Compugen (CGEN), Telix Pharmaceuticals (OtherTLPPF) and Sarepta Therapeutics (SRPT)

TIPRANKS
·
Jul 22

Has Sarepta Therapeutics (SRPT) Fallen Below Fair Value After FDA Progress?

Simply Wall St.
·
Jul 19

Is Sarepta Therapeutics (SRPT) Undervalued Following FDA Progress On AMONDYS 45 And VYONDYS 53?

Simply Wall St.
·
Jul 15

Analysts Offer Insights on Healthcare Companies: Forte Biosciences (FBRX), Sarepta Therapeutics (SRPT) and Opus Genetics (IRD)

TIPRANKS
·
Jul 10

Sarepta Therapeutics Raised to Outperform from Peer Perform by Wolfe Research

Dow Jones
·
Jul 09

Sarepta price target lowered to $20 from $23 at Piper Sandler

TIPRANKS
·
Jul 09

Sarepta upgraded to Outperform from Peer Perform at Wolfe Research

TIPRANKS
·
Jul 09

Why Sarepta Therapeutics (SRPT) Is Up 12.7% After FDA Accepts sNDAs Backed By ESSENCE Data

Simply Wall St.
·
Jul 08

H.C. Wainwright says Sarepta news does not signal full approvals

TIPRANKS
·
Jul 01

Sarepta Grants 151,305 Rsus to 30 New Hires Under 2024 Incentive Plan

Reuters
·
Jul 01